Effectiveness of Coronavirus Vaccines against Syndrome Coronavirus 2 (SARS-CoV-2) and Its New Variants
Pro and Cons of Coronavirus Vaccines
Abstract
The widespread outbreak of coronavirus disease 2019 in late 2019 caused many people worldwide to die or suffer from certain clinical complications even after the recovery. The virus has many social and economic adverse effects. Studies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have specified that spike, surface glycoprotein antigen, is considered as a major target to stimulate the immune system. This glycoprotein binds to the angiotensin-converting enzyme 2 on the surface of human cells especially lung epithelial cells and facilitates the virus entry. Therefore, the immune response stimulated by vaccination targeting this antigen may cause immunity against the whole virus. Currently, many companies are working on SARS-CoV-2 vaccines. They include ‘traditional’ vaccines like attenuated or inactivated virus platforms as well as the brand-new generations of vaccines such as viral vector-based, subunit, nucleic acid-based, and virus-like particle vaccines. Certainly, each vaccine platform presents several advantages and disadvantages affecting its efficacy and safety which is the main topic of this paper.
1. Zhong N, Zheng B, Li Y, Poon L, Xie Z, Chan K, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet. 2003;362(9393):1353-8.
2. Nourizadeh M, Rasaee MJ, Moin M. COVID-19 Pandemic: A Big Challenge in Iran and the World. Iran J Allergy Asthma Immunol. 2020;19(S1):1-2.
3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(7):727-33.
4. Mostafaei A, Ghojazadeh M, Hajebrahimi S, Abolhasanpour N, Salehi-Pourmehr H. Clinical Presentation of Iranian Patients Affected with COVID-19: A Thousand Faces Disease. Iran J Allergy Asthma Immunol. 2021;20(2):140-6.
5. Ghazanfari T, Salehi MR, Namaki S, Arabkheradmand J, Rostamian A, Rajabnia Chenary M, et al. Interpretation of Hematological, Biochemical, and Immunological Findings of COVID-19 Disease: Biomarkers Associated with Severity and Mortality. Iran J Allergy Asthma Immunol. 2021;20(1):46-66.
6. Seow J, Graham C, Merrick B, Acors S, Steel KJ, Hemmings O, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. Med Rxiv. 2020;7(9):20148429.
7. Tregoning JS, Brown ES, Cheeseman HM, Flight KE, Higham SL, Lemm NM, et al. Vaccines for COVID-19. Clin Exp Immunol. 2020;202(2):162-92.
8. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382-5.
9. Al-Kassmy J, Pedersen J, Kobinger G. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? Viruses. 2020;12(8):861-9.
10. Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-36.
11. Kim J-M, Chung Y-S, Jo HJ, Lee N-J, Kim MS, Woo SH, et al. Identification of Coronavirus Isolated from a Patient in Korea with COVID-19. Osong Public Health Res Perspect. 2020;11(1):3-7.
12. Sariol A, Perlman S. Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity. 2020;53(2):248-63.
13. Islam MR, Hoque MN, Rahman MS, Alam ASMRU, Akther M, Puspo JA, et al. Genome-wide analysis of SARS-CoV-2 virus strains circulating worldwide implicates heterogeneity. Sci Rep. 2020;10(1):14004.
14. Musavi H, Abazari O, Safaee MS, Variji A, Koohshekan B, Kalaki-Jouybari F, et al. Mechanisms of COVID-19 Entry into the Cell: Potential Therapeutic Approaches Based on Virus Entry Inhibition in COVID-19 Patients with Underlying Diseases. Iran J Allergy Asthma Immunol. 2021;20(1):11-23.
15. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23.
16. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-3.
17. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801-11.
18. Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020;17(7):765-7.
19. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.
20. Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004;363(9413):938-47.
21. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-32.
22. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.
23. Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus A, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251-5.
24. Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurlburt NK, Jennewein MF, et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity. 2020;53(1):98-105.
25. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650-5.
26. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650-5.
27. Grant OC, Montgomery D, Ito K, Woods RJ. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Sci Rep. 2020;10(1):1-11.
28. Su S, Du L, Jiang S. Learning from the past: development of safe and effective COVID-19 vaccines. Nat Rev Microbiol. 2021;19(3):211-9.
29. Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586(7830):572-7.
30. Jiaming L, Yanfeng Y, Yao D, Yawei H, Linlin B, Baoying H, et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2017;35(1):10-8.
31. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339-43.
32. Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;369(6501):330-3.
33. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181(7):1489-501.e15.
34. Sun J, Zhuang Z, Zheng J, Li K, Wong RL-Y, Liu D, et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell. 2020;182(3):734-43. e5.
35. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845-8.
36. Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol. 2008;181(9):6337-48.
37. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73-82.
38. Bos R, Rutten L, van der Lubbe JEM, Bakkers MJG, Hardenberg G, Wegmann F, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. BioRxiv. 2020;7(30):227470.
39. Bangaru S, Ozorowski G, Turner HL, Antanasijevic A, Huang D, Wang X, et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science. 2020;370(6520):1089-94.
40. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
41. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2.
42. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-74.
43. Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol. 2014;88(19):11034-44.
44. Zhang F, Gan R, Zhen Z, Hu X, Li X, Zhou F, et al. Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals. Signal Transduct Target Ther. 2020;5(1):156.
45. Ni L, Ye F, Cheng M-L, Feng Y, Deng Y-Q, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;5286(14):971-7.
46. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396(10262):1095-606.
47. Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996-1012.
48. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489-501.
49. Le Bert N, Tan AT, Kunasegaran K, Tham CY, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457-62.
50. Fontanet A, Cauchemez S. COVID-19 herd immunity: where are we? Nat Rev Immunol. 2020;20(10):583-4.
51. Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science. 2020;369(6505):818-23.
52. Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, et al. Molecular architecture of early dissemination and massive second wave of the SARS-CoV-2 virus in a major metropolitan area. mBio. 2020;11(6):e02707-20.
53. Mak TW, Saunders ME. The immune response. Basic and clinical principles: Elsevier; 1st. Academic Press. 2006;469-74.
54. Food, Administration D. Coronavirus (COVID-19) Update: FDA Takes Actionto Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines. WHO. 2020. Episode#26.
55. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
56. Oliveira SC, Rosinha GMS, de-Brito CFA, Fonseca CT, Afonso RR, Costa MCMS, et al. Immunological properties of gene vaccines delivered by different routes. Brazilian Journal of Medical and Biological Research.Braz J Med Biol Res. 1999;32(2): 207-14.
57. Bandehpour M, Khodabandeh M, Kazemi B. Cloning and Expression of Hepatitis B Surface Antigen. Hepat Mon.8(1):17-21.
58. Mehdinejadiani K, Bandehpour M, Hashemi A, Ranjbar MM, Taheri S, Jalali SA, et al. In Silico Design and Evaluation of Acinetobacter baumannii Outer Membrane Protein a Antigenic Peptides As Vaccine Candidate in Immunized Mice. Iran J Allergy Asthma Immunol. 2019;18(6):655-63.
59. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004;10(8):871-5.
60. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.
61. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;183(6):1735.
62. Sautto GA, Kirchenbaum GA, Diotti RA, Criscuolo E, Ferrara F. Next Generation Vaccines for Infectious Diseases. J Immunol Res. 2019;2019:5890962.
63. Côté-Gravel J, Brouillette E, Malouin F. Vaccination with a live-attenuated small-colony variant improves the humoral and cell-mediated responses against Staphylococcus aureus. PloSOne. 2019;14(12):e0227109.
64. Xie X, Kum DB, Xia H, Luo H, Shan C, Zou J, et al. A single-dose live-attenuated Zika virus vaccine with controlled infection rounds that protects against vertical transmission. Cell Host Microbe. 2018;24(4):487-99. e5.
65. de Boer PT, van Lier A, de Melker H, van Wijck AJ, Wilschut JC, van Hoek AJ, et al. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Med. 2018;16(1):228-31.
66. Roper RL, Rehm KE. SARS vaccines: where are we? Expert Rev Vaccines. 2009;8(7):887-98.
67. Kamboj M, Sepkowitz KA. Risk of Transmission Associated With Live Attenuated Vaccines Given to Healthy Persons Caring for or Residing With an Immunocompromised Patient. Infect Control Hosp Epidemiol. 2007;28(6):702-7.
68. Harper SA, Fukuda K, Cox NJ, Bridges CB. Using live, attenuated influenza vaccine for prevention and control of influenza. MMWR Recomm Rep. 2003;52(3):1-8.
69. Selvapandiyan A, Dey R, Gannavaram S, Solanki S, Salotra P, Nakhasi HL. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis. Vaccine. 2014;32(31):3895-901.
70. Boumart Z, Daouam S, Belkourati I, Rafi L, Tuppurainen E, Tadlaoui KO, et al. Comparative innocuity and efficacy of live and inactivated sheeppox vaccines. BMC Vet Res. 2016;12(1):1-6.
71. Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M. Understanding modern-day vaccines: what you need to know. Ann Med. 2018;50(2):110-20.
72. Toman M, Celer V, Kavanová L, Levá L, Frolichova J, Ondráčková P, et al. Dynamics and Differences in Systemic and Local Immune Responses After Vaccination With Inactivated and Live Commercial Vaccines and Subsequent Subclinical Infection With PRRS Virus. Front Immunol. 2019;10(9):1689-91.
73. Van TTH, Lin Y-C, Color PJ, Smooker PM. From animals to humans: can vaccines make the transition. Nova Science Publishers: Hauppauge, NY, USA; 2012; 1-63.
74. Sanders B, Koldijk M, Schuitemaker H. Inactivated Viral Vaccines. In: Nunnally B., Turula V., Sitrin R. (eds) Vaccine Analysis: Strategies, Principles, and Control. Springer, Berlin, Heidelberg.2015; 45-80.
75. Strugnell R, Zepp F, Cunningham A, Tantawichien T. Vaccine antigens. Perspect Vaccinol. 2011;1(1):61-88.
76. Kumar A, McElhaney JE, Walrond L, Cyr TD, Merani S, Kollmann TR, et al. Cellular immune responses of older adults to four influenza vaccines: results of a randomized, controlled comparison. Hum Vaccin Immunother. 2017;13(9):2048-57.
77. Arrington J, Braun RP, Dong L, Fuller DH, Macklin MD, Umlauf SW, et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol. 2002;76(9):4536-46.
78. Liu MA. A comparison of plasmid DNA and mrna as vaccine technologies. Vaccines. 2019;7(2):37.
79. Azizi H, Kazemi B, Bandehpour M, Mohebali M, Khamesipour A, Aryaeipour M, et al. Modulation of the Immune Response to DNA Vaccine Encoding Gene of 8-kDa Subunit of Echinococcus granulosus Antigen B Using Murine Interleukin-12 Plasmid in BALB/c Mice. Iran J Parasitol. 2016;11(4):480-9.
80. Johansson P, Lindgren T, Lundström M, Holmström A, Elgh F, Bucht G. PCR-generated linear DNA fragments utilized as a hantavirus DNA vaccine. Vaccine. 2002;20(27-28):3379-88.
81. Schmeer M, Buchholz T, Schleef M. Plasmid DNA manufacturing for indirect and direct clinical applications. Human Gene Ther. 2017;28(10):856-61.
82. Wu M, Zhao H, Li M, Yue Y, Xiong S, Xu W. Intranasal vaccination with mannosylated chitosan formulated DNA vaccine enables robust IgA and cellular response induction in the lungs of mice and improves protection against pulmonary mycobacterial challenge. Front Cell Infect Microbiol. 2017;7(2):445-8.
83. Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19(9):1013-22.
84. Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021;28(3-4):117-29.
85. Jackson NA, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: A biotech and industrial perspective. NPJ Vaccines. 2020;5(1):1-6.
86. Sharifnia Z, Bandehpour M, Kazemi B, Zarghami N. Design and Development of Modified mRNA Encoding Core Antigen of Hepatitis C Virus: a Possible Application in Vaccine Production. Iran Biomed J. 2019;23(1):57-67.
87. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16.
88. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15.
89. Zhang N-N, Li X-F, Deng Y-Q, Zhao H, Huang Y-J, Yang G, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271-83.
90. Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511-20.
91. Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet. 2021;397(10278):952-4.
92. Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines. 2014;2(3):624-41.
93. Van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19(8):810-2.
94. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 2005;174(11):7179-85.
95. Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994;91(10):4407-11.
96. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
97. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-81.
98. Hu J, Ni Y, Dryman BA, Meng X, Zhang C. Immunogenicity study of plant-made oral subunit vaccine against porcine reproductive and respiratory syndrome virus (PRRSV). Vaccine. 2012;30(12):2068-74.
99. Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, de la Barrera S, et al. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine. 2007;25(22):4437-46.
100. Rajan V. An Oral Vaccine for TGEV Immunization of Pigs. Commercial Plant-Produced Recombinant Protein Products: Springer. 2014; 135-52.
101. Daniell H. Production of biopharmaceuticals and vaccines in plants via the chloroplast genome. Biotechnol J Healthcare Nutr Technol. 2006;1(10):1071-9.
102. Cappel R. Comparison of the humoral and cellular immune responses after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations. Arch Virol. 1976;52(1-2):29-35.
103. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine. 2001;19(17-19):2666-72.
104. Nevagi RJ, Skwarczynski M, Toth I. Polymers for subunit vaccine delivery. European Polymer Journal. 2019;114(17):397-410.
105. Foged C, Rades T, Perrie Y, Hook S. Subunit vaccine delivery: Springer. 2015: XIV, 431.
106. Pankrac J, Klein K, McKay PF, King DF, Bain K, Knapp J, et al. A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. NPJ vaccines. 2018;3(1):1-10.
107. Wang JW, Roden RB. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert RevVaccines. 2013;12(2):129-41.
108. Dai S, Wang H, Deng F. Advances and challenges in enveloped virus-like particle (VLP)-based vaccines. J Immunol Sci. 2018;2(2):36-41.
109. Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF, editors. Major findings and recent advances in virus–like particle (VLP)-based vaccines. Semin Immunol. 2017;34(8):123-32.
110. Madrid-Marina V, Torres-Poveda K, López-Toledo G, García-Carrancá A. Advantages and Disadvantages of Current Prophylactic Vaccines Against HPV. Arch Med Res. 2009;40(6):471-7.
111. Zhang Y, Zeng G, Pan H, Li C, Kan B, Hu Y, et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. Med Rxiv. 2020;(31):20161216.
112. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020;324(10):951-60.
113. Dey A, Chozhavel Rajanathan TM, Chandra H, Pericherla HPR, Kumar S, Choonia HS, et al. Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models. bioRxiv. 2021;1(26):428240-8.
114. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2—preliminary report. N Eng J Med. 2020;383(25):1920-31.
115. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-93.
116. Zhang N-N, Li X-F, Deng Y-Q, Zhao H, Huang Y-J, Yang G, et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020;182(5):1271-83.e16.
117. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78.
118. van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586(7830):578-82.
119. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-97.
120. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. New Eng J Med. 2021;384(23):2187-201.
121. Mahase E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021;372:n296.
122. Ward BJ, Gobeil P, Séguin A, Atkins J, Boulay I, Charbonneau P-Y, et al. Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants. Med Rxiv. 2020;11(4):20226282.
123. Wareing M, Tannock G. Live attenuated vaccines against influenza; an historical review. Vaccine. 2001;19(25-26):3320-30.
124. Ni L, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004;292(14):1696-701.
125. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-10):1-42.
126. Wharton M, Strikas R, Harpaz R, Rotz L, Schwartz B, Casey C. Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee: Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices. Advisory Committee (HICPAC). MMWR Recomm Rep. 2003;52(RR-7):1-16.
127. Watson J, Hadler S, Dykewicz C, Reef S, Phillips L. Vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1998;47(8):1-57.
128. Draft Landscape of COVID-19 Candidate Vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
129. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713-21.
130. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81.
131. Stauffer F, El-Bacha T, Da Poian AT. Advances in the development of inactivated virus vaccines. Recent Pat Antiinfect Drug Discov. 2006;1(3):291-6.
132. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines. 2009;8(5):607-18.
133. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, et al. The virosome concept for influenza vaccines. Vaccine. 2005;23:S26-S38.
134. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-92.
135. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines. 2009;8(5):607-18.
136. Smith TR, Schultheis K, Broderick KE. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods. Hum Vaccin Immunother. 2017;13(11):2626-9.
137. Cui Z. DNA vaccine. Adv Genet. 2005;54:257-89.
138. Authority EFS, Houston R, Moxon S, Nogué F, Papadopoulou N, Ramon M, et al. Assessment of the potential integration of the DNA plasmid vaccine CLYNAV into the salmon genome. EFSA J. 2017;15(1):e04689.
139. Nichols WW, Ledwith BJ, Manam SV, Troilo PJ. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci. 1995;772:30-9.
140. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res. 2008;42(1-3):219-32.
141. Gottlieb P, Utz PJ, Robinson W, Steinman L. Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform. Clinic Immunol. 2013;149(3):297-306.
142. Edwards DK, Jasny E, Yoon H, Horscroft N, Schanen B, Geter T, et al. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J Transl Med. 2017;15(1):1-18.
143. Fuller DH, Berglund P. Amplifying RNA vaccine development. N Engl J Med. 2020;382(25):2469-71.
144. Zhang L, Bai J, Liu J, Wang X, Li Y, Jiang P. Toll-like receptor ligands enhance the protective effects of vaccination against porcine reproductive and respiratory syndrome virus in swine. Vet Microbiol. 2013;164(3-4):253-60.
145. Reautschnig P, Vogel P, Stafforst T. The notorious RNA in the spotlight-drug or target for the treatment of disease. RNA biology. 2017;14(5):651-68.
146. Douville RN, Nath A. Human endogenous retroviruses and the nervous system. Handb Clin Neurol. 2014;123(12):465-85.
147. Campbell JD. Development of the CpG adjuvant 1018: a case study. Methods Mol Biol. 2017;1494(26):15-27.
148. Blakney AK, McKay PF, Yus BI, Aldon Y, Shattock RJ. Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Gene Ther. 2019;26(9):363-72.
149. Sekaly R-P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med. 2008;205(1):7-12.
150. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-20.
151. Dicks MDJ, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, et al. A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLOS ONE. 2012;7(7):e40385.
152. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med. 2008;14(6):617-21.
153. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clinic Infect Dis. 2008;46(11):1769-81.
154. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-97.
155. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78.
156. Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem. 2013;8(3):360-76.
157. Karch CP, Burkhard P. Vaccine technologies: From whole organisms to rationally designed protein assemblies. Biochem Pharmacol. 2016;120(9):1-14.
158. Eyigün CP, Yilmaz S, Gül C, Sengül A, Hacibektasoglu A, Van Thiel DH. A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults. J Viral Hepat. 1998;5(4):265-9.
159. Feenstra F, Van Rijn PA. Current and next-generation bluetongue vaccines: Requirements, strategies, and prospects for different field situations. Crit Rev Microbiol. 2017;43(2):142-55.
160. Keech C, Albert G, Reed P, Neal S, Plested JS, Zhu M, et al. First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine. MedRxiv. 2020;8(5):20168435.
161. Lövgren K, Morein B. The requirement of lipids for the formation of immunostimulating complexes (iscoms). Biotechnol Appl Biochem. 1988;10(2):161-72.
162. Magnusson SE, Altenburg AF, Bengtsson KL, Bosman F, de Vries RD, Rimmelzwaan GF, et al. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66(2):224-33.
163. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787-96.
164. Grgacic EVL, Anderson DA. Virus-like particles: Passport to immune recognition. Methods. 2006;40(1):60-5.
165. Andrus JK, Sherris J, Fitzsimmons JW, Kane MA, Aguado MT. Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement. Vaccine. 2008;26(Suppl 10):K87-92.
166. Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines. 2012;11(3):349-66.
167. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med. 2020;384(7):643-9.
168. Stone Jr CA, Rukasin CR, Beachkofsky TM, Phillips EJ. Immune‐mediated adverse reactions to vaccines. Br J Clin Pharmacol. 2019;85(12):2694-706.
169. Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem. 2021;36(4):1-13.
170. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
171. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-97.
172. Sadoff J, Gars ML, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. MedRxiv. 2020;9(23):20199604.
173. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383(24):2320-32.
174. Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152. MedRxiv. 2020;12(11):20210419.
175. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html.
176. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications. N Engl J Med. 2021;384(19):1866-8.
177. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. MedRxiv. 2020;12(24):20248822.
178. Davies NG, Jarvis CI, CMMID COVID-19 Working Group, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593: 270–274.
179. Reuschl AK, Thorne L, Zuliani Alvarez L, Bouhaddou M, Obernier K, Soucheray M, et al. Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant. bioRxiv. 2021;24:427991.
180. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. bioRxiv. 2021;1(25):428137.
181. Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. MedRxiv. 2021;3(7):21252647.
182. Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Alshammary H, Amoako AA, et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe. 2021;2(7):e283-e284.
183. Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. BioRxiv. 2021;4(23):441101.
184. Gupta RK. Will SARS-CoV-2 variants of concern affect the promise of vaccines? Nat Rev Immunol. 2021;21(8):340–341.
185. Kemp S, Harvey W, Datir R, Collier D, Ferreira I, Carabelii A, et al. Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/V70. bioRxiv. 2020:2020.12.14.422555.
186. Collier DA, De Marco A, Ferreira IA, Meng B, Datir RP, Walls AC, et al. Sensitivity of SARS-CoV-2 B. 1.1. 7 to mRNA vaccine-elicited antibodies. Nature. 2021:1-10.
187. Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, et al. Increased Resistance of SARS-CoV-2 Variant P. 1 to Antibody Neutralization. Cell Host Microbe. 2021:2021.03.01.433466.
188. Hon C-C, Lam T-Y, Shi Z-L, Drummond AJ, Yip C-W, Zeng F, et al. Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus. J Virol. 2008;82(4):1819-26.
189. Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, Rapp M, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021;29(5):819-33.
190. Fratev F. The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: A Free energy of perturbation study. bioRxiv. 2020:2020.12.23.424283.
191. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell host & microbe. 2021;29(1):44-57.
192. Bian L, Gao F, Zhang J, He Q, Mao Q, Xu M, et al. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert review of vaccines. 2021:1-9.
193. Tchesnokova V, Kulakesara H, Larson L, Bowers V, Rechkina E, Kisiela D, et al. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. bioRxiv. 2021:2021.02.22.432189.
194. Mohammadi E, Shafiee F, Shahzamani K, Ranjbar MM, Alibakhshi A, Ahangarzadeh S, et al. Novel and emerging mutations of SARS-CoV-2: Biomedical implications. Biomed Pharmacother. 2021;139:111599.
195. Shinde V, Bhikha S, Hossain Z, Archary M, Bhorat Q, Fairlie L, et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant. med Rxiv. 2021:2021.02.25.21252477.
196. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant. N Engl J Med. 2021;384(20):1885-98.
197. Cohen J. South Africa suspends use of AstraZeneca's COVID-19 vaccine after it fails to clearly stop virus variant. Science. 2021:2-7.
198. Wadman M, Cohen J. Novavax vaccine delivers 89% efficacy against COVID-19 in UK—but is less potent in South Africa. Science. 2021;12(2774).
199. Hitchings M, Ranzani OT, Torres MS, de Oliveira SB, Almiron M, Said R, et al. Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P. 1 variant transmission in Brazil: A test-negative case-control study. medRxiv. 2021:2021.04.07.21255081.
200. Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52(5):737-41.
2. Nourizadeh M, Rasaee MJ, Moin M. COVID-19 Pandemic: A Big Challenge in Iran and the World. Iran J Allergy Asthma Immunol. 2020;19(S1):1-2.
3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(7):727-33.
4. Mostafaei A, Ghojazadeh M, Hajebrahimi S, Abolhasanpour N, Salehi-Pourmehr H. Clinical Presentation of Iranian Patients Affected with COVID-19: A Thousand Faces Disease. Iran J Allergy Asthma Immunol. 2021;20(2):140-6.
5. Ghazanfari T, Salehi MR, Namaki S, Arabkheradmand J, Rostamian A, Rajabnia Chenary M, et al. Interpretation of Hematological, Biochemical, and Immunological Findings of COVID-19 Disease: Biomarkers Associated with Severity and Mortality. Iran J Allergy Asthma Immunol. 2021;20(1):46-66.
6. Seow J, Graham C, Merrick B, Acors S, Steel KJ, Hemmings O, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. Med Rxiv. 2020;7(9):20148429.
7. Tregoning JS, Brown ES, Cheeseman HM, Flight KE, Higham SL, Lemm NM, et al. Vaccines for COVID-19. Clin Exp Immunol. 2020;202(2):162-92.
8. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382-5.
9. Al-Kassmy J, Pedersen J, Kobinger G. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? Viruses. 2020;12(8):861-9.
10. Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-36.
11. Kim J-M, Chung Y-S, Jo HJ, Lee N-J, Kim MS, Woo SH, et al. Identification of Coronavirus Isolated from a Patient in Korea with COVID-19. Osong Public Health Res Perspect. 2020;11(1):3-7.
12. Sariol A, Perlman S. Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity. 2020;53(2):248-63.
13. Islam MR, Hoque MN, Rahman MS, Alam ASMRU, Akther M, Puspo JA, et al. Genome-wide analysis of SARS-CoV-2 virus strains circulating worldwide implicates heterogeneity. Sci Rep. 2020;10(1):14004.
14. Musavi H, Abazari O, Safaee MS, Variji A, Koohshekan B, Kalaki-Jouybari F, et al. Mechanisms of COVID-19 Entry into the Cell: Potential Therapeutic Approaches Based on Virus Entry Inhibition in COVID-19 Patients with Underlying Diseases. Iran J Allergy Asthma Immunol. 2021;20(1):11-23.
15. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23.
16. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-3.
17. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801-11.
18. Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020;17(7):765-7.
19. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.
20. Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004;363(9413):938-47.
21. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-32.
22. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.
23. Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus A, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251-5.
24. Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurlburt NK, Jennewein MF, et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity. 2020;53(1):98-105.
25. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650-5.
26. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650-5.
27. Grant OC, Montgomery D, Ito K, Woods RJ. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Sci Rep. 2020;10(1):1-11.
28. Su S, Du L, Jiang S. Learning from the past: development of safe and effective COVID-19 vaccines. Nat Rev Microbiol. 2021;19(3):211-9.
29. Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586(7830):572-7.
30. Jiaming L, Yanfeng Y, Yao D, Yawei H, Linlin B, Baoying H, et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2017;35(1):10-8.
31. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339-43.
32. Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;369(6501):330-3.
33. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181(7):1489-501.e15.
34. Sun J, Zhuang Z, Zheng J, Li K, Wong RL-Y, Liu D, et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell. 2020;182(3):734-43. e5.
35. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845-8.
36. Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol. 2008;181(9):6337-48.
37. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73-82.
38. Bos R, Rutten L, van der Lubbe JEM, Bakkers MJG, Hardenberg G, Wegmann F, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. BioRxiv. 2020;7(30):227470.
39. Bangaru S, Ozorowski G, Turner HL, Antanasijevic A, Huang D, Wang X, et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science. 2020;370(6520):1089-94.
40. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
41. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2.
42. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-74.
43. Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol. 2014;88(19):11034-44.
44. Zhang F, Gan R, Zhen Z, Hu X, Li X, Zhou F, et al. Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals. Signal Transduct Target Ther. 2020;5(1):156.
45. Ni L, Ye F, Cheng M-L, Feng Y, Deng Y-Q, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;5286(14):971-7.
46. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396(10262):1095-606.
47. Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996-1012.
48. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489-501.
49. Le Bert N, Tan AT, Kunasegaran K, Tham CY, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457-62.
50. Fontanet A, Cauchemez S. COVID-19 herd immunity: where are we? Nat Rev Immunol. 2020;20(10):583-4.
51. Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science. 2020;369(6505):818-23.
52. Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, et al. Molecular architecture of early dissemination and massive second wave of the SARS-CoV-2 virus in a major metropolitan area. mBio. 2020;11(6):e02707-20.
53. Mak TW, Saunders ME. The immune response. Basic and clinical principles: Elsevier; 1st. Academic Press. 2006;469-74.
54. Food, Administration D. Coronavirus (COVID-19) Update: FDA Takes Actionto Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines. WHO. 2020. Episode#26.
55. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
56. Oliveira SC, Rosinha GMS, de-Brito CFA, Fonseca CT, Afonso RR, Costa MCMS, et al. Immunological properties of gene vaccines delivered by different routes. Brazilian Journal of Medical and Biological Research.Braz J Med Biol Res. 1999;32(2): 207-14.
57. Bandehpour M, Khodabandeh M, Kazemi B. Cloning and Expression of Hepatitis B Surface Antigen. Hepat Mon.8(1):17-21.
58. Mehdinejadiani K, Bandehpour M, Hashemi A, Ranjbar MM, Taheri S, Jalali SA, et al. In Silico Design and Evaluation of Acinetobacter baumannii Outer Membrane Protein a Antigenic Peptides As Vaccine Candidate in Immunized Mice. Iran J Allergy Asthma Immunol. 2019;18(6):655-63.
59. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004;10(8):871-5.
60. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.
61. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;183(6):1735.
62. Sautto GA, Kirchenbaum GA, Diotti RA, Criscuolo E, Ferrara F. Next Generation Vaccines for Infectious Diseases. J Immunol Res. 2019;2019:5890962.
63. Côté-Gravel J, Brouillette E, Malouin F. Vaccination with a live-attenuated small-colony variant improves the humoral and cell-mediated responses against Staphylococcus aureus. PloSOne. 2019;14(12):e0227109.
64. Xie X, Kum DB, Xia H, Luo H, Shan C, Zou J, et al. A single-dose live-attenuated Zika virus vaccine with controlled infection rounds that protects against vertical transmission. Cell Host Microbe. 2018;24(4):487-99. e5.
65. de Boer PT, van Lier A, de Melker H, van Wijck AJ, Wilschut JC, van Hoek AJ, et al. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Med. 2018;16(1):228-31.
66. Roper RL, Rehm KE. SARS vaccines: where are we? Expert Rev Vaccines. 2009;8(7):887-98.
67. Kamboj M, Sepkowitz KA. Risk of Transmission Associated With Live Attenuated Vaccines Given to Healthy Persons Caring for or Residing With an Immunocompromised Patient. Infect Control Hosp Epidemiol. 2007;28(6):702-7.
68. Harper SA, Fukuda K, Cox NJ, Bridges CB. Using live, attenuated influenza vaccine for prevention and control of influenza. MMWR Recomm Rep. 2003;52(3):1-8.
69. Selvapandiyan A, Dey R, Gannavaram S, Solanki S, Salotra P, Nakhasi HL. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis. Vaccine. 2014;32(31):3895-901.
70. Boumart Z, Daouam S, Belkourati I, Rafi L, Tuppurainen E, Tadlaoui KO, et al. Comparative innocuity and efficacy of live and inactivated sheeppox vaccines. BMC Vet Res. 2016;12(1):1-6.
71. Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M. Understanding modern-day vaccines: what you need to know. Ann Med. 2018;50(2):110-20.
72. Toman M, Celer V, Kavanová L, Levá L, Frolichova J, Ondráčková P, et al. Dynamics and Differences in Systemic and Local Immune Responses After Vaccination With Inactivated and Live Commercial Vaccines and Subsequent Subclinical Infection With PRRS Virus. Front Immunol. 2019;10(9):1689-91.
73. Van TTH, Lin Y-C, Color PJ, Smooker PM. From animals to humans: can vaccines make the transition. Nova Science Publishers: Hauppauge, NY, USA; 2012; 1-63.
74. Sanders B, Koldijk M, Schuitemaker H. Inactivated Viral Vaccines. In: Nunnally B., Turula V., Sitrin R. (eds) Vaccine Analysis: Strategies, Principles, and Control. Springer, Berlin, Heidelberg.2015; 45-80.
75. Strugnell R, Zepp F, Cunningham A, Tantawichien T. Vaccine antigens. Perspect Vaccinol. 2011;1(1):61-88.
76. Kumar A, McElhaney JE, Walrond L, Cyr TD, Merani S, Kollmann TR, et al. Cellular immune responses of older adults to four influenza vaccines: results of a randomized, controlled comparison. Hum Vaccin Immunother. 2017;13(9):2048-57.
77. Arrington J, Braun RP, Dong L, Fuller DH, Macklin MD, Umlauf SW, et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol. 2002;76(9):4536-46.
78. Liu MA. A comparison of plasmid DNA and mrna as vaccine technologies. Vaccines. 2019;7(2):37.
79. Azizi H, Kazemi B, Bandehpour M, Mohebali M, Khamesipour A, Aryaeipour M, et al. Modulation of the Immune Response to DNA Vaccine Encoding Gene of 8-kDa Subunit of Echinococcus granulosus Antigen B Using Murine Interleukin-12 Plasmid in BALB/c Mice. Iran J Parasitol. 2016;11(4):480-9.
80. Johansson P, Lindgren T, Lundström M, Holmström A, Elgh F, Bucht G. PCR-generated linear DNA fragments utilized as a hantavirus DNA vaccine. Vaccine. 2002;20(27-28):3379-88.
81. Schmeer M, Buchholz T, Schleef M. Plasmid DNA manufacturing for indirect and direct clinical applications. Human Gene Ther. 2017;28(10):856-61.
82. Wu M, Zhao H, Li M, Yue Y, Xiong S, Xu W. Intranasal vaccination with mannosylated chitosan formulated DNA vaccine enables robust IgA and cellular response induction in the lungs of mice and improves protection against pulmonary mycobacterial challenge. Front Cell Infect Microbiol. 2017;7(2):445-8.
83. Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19(9):1013-22.
84. Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021;28(3-4):117-29.
85. Jackson NA, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: A biotech and industrial perspective. NPJ Vaccines. 2020;5(1):1-6.
86. Sharifnia Z, Bandehpour M, Kazemi B, Zarghami N. Design and Development of Modified mRNA Encoding Core Antigen of Hepatitis C Virus: a Possible Application in Vaccine Production. Iran Biomed J. 2019;23(1):57-67.
87. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16.
88. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15.
89. Zhang N-N, Li X-F, Deng Y-Q, Zhao H, Huang Y-J, Yang G, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271-83.
90. Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511-20.
91. Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet. 2021;397(10278):952-4.
92. Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines. 2014;2(3):624-41.
93. Van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19(8):810-2.
94. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 2005;174(11):7179-85.
95. Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994;91(10):4407-11.
96. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
97. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-81.
98. Hu J, Ni Y, Dryman BA, Meng X, Zhang C. Immunogenicity study of plant-made oral subunit vaccine against porcine reproductive and respiratory syndrome virus (PRRSV). Vaccine. 2012;30(12):2068-74.
99. Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, de la Barrera S, et al. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine. 2007;25(22):4437-46.
100. Rajan V. An Oral Vaccine for TGEV Immunization of Pigs. Commercial Plant-Produced Recombinant Protein Products: Springer. 2014; 135-52.
101. Daniell H. Production of biopharmaceuticals and vaccines in plants via the chloroplast genome. Biotechnol J Healthcare Nutr Technol. 2006;1(10):1071-9.
102. Cappel R. Comparison of the humoral and cellular immune responses after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations. Arch Virol. 1976;52(1-2):29-35.
103. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine. 2001;19(17-19):2666-72.
104. Nevagi RJ, Skwarczynski M, Toth I. Polymers for subunit vaccine delivery. European Polymer Journal. 2019;114(17):397-410.
105. Foged C, Rades T, Perrie Y, Hook S. Subunit vaccine delivery: Springer. 2015: XIV, 431.
106. Pankrac J, Klein K, McKay PF, King DF, Bain K, Knapp J, et al. A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. NPJ vaccines. 2018;3(1):1-10.
107. Wang JW, Roden RB. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert RevVaccines. 2013;12(2):129-41.
108. Dai S, Wang H, Deng F. Advances and challenges in enveloped virus-like particle (VLP)-based vaccines. J Immunol Sci. 2018;2(2):36-41.
109. Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF, editors. Major findings and recent advances in virus–like particle (VLP)-based vaccines. Semin Immunol. 2017;34(8):123-32.
110. Madrid-Marina V, Torres-Poveda K, López-Toledo G, García-Carrancá A. Advantages and Disadvantages of Current Prophylactic Vaccines Against HPV. Arch Med Res. 2009;40(6):471-7.
111. Zhang Y, Zeng G, Pan H, Li C, Kan B, Hu Y, et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. Med Rxiv. 2020;(31):20161216.
112. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020;324(10):951-60.
113. Dey A, Chozhavel Rajanathan TM, Chandra H, Pericherla HPR, Kumar S, Choonia HS, et al. Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models. bioRxiv. 2021;1(26):428240-8.
114. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2—preliminary report. N Eng J Med. 2020;383(25):1920-31.
115. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-93.
116. Zhang N-N, Li X-F, Deng Y-Q, Zhao H, Huang Y-J, Yang G, et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020;182(5):1271-83.e16.
117. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78.
118. van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586(7830):578-82.
119. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-97.
120. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. New Eng J Med. 2021;384(23):2187-201.
121. Mahase E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021;372:n296.
122. Ward BJ, Gobeil P, Séguin A, Atkins J, Boulay I, Charbonneau P-Y, et al. Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants. Med Rxiv. 2020;11(4):20226282.
123. Wareing M, Tannock G. Live attenuated vaccines against influenza; an historical review. Vaccine. 2001;19(25-26):3320-30.
124. Ni L, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004;292(14):1696-701.
125. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-10):1-42.
126. Wharton M, Strikas R, Harpaz R, Rotz L, Schwartz B, Casey C. Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee: Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices. Advisory Committee (HICPAC). MMWR Recomm Rep. 2003;52(RR-7):1-16.
127. Watson J, Hadler S, Dykewicz C, Reef S, Phillips L. Vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1998;47(8):1-57.
128. Draft Landscape of COVID-19 Candidate Vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
129. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713-21.
130. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81.
131. Stauffer F, El-Bacha T, Da Poian AT. Advances in the development of inactivated virus vaccines. Recent Pat Antiinfect Drug Discov. 2006;1(3):291-6.
132. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines. 2009;8(5):607-18.
133. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, et al. The virosome concept for influenza vaccines. Vaccine. 2005;23:S26-S38.
134. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-92.
135. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines. 2009;8(5):607-18.
136. Smith TR, Schultheis K, Broderick KE. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods. Hum Vaccin Immunother. 2017;13(11):2626-9.
137. Cui Z. DNA vaccine. Adv Genet. 2005;54:257-89.
138. Authority EFS, Houston R, Moxon S, Nogué F, Papadopoulou N, Ramon M, et al. Assessment of the potential integration of the DNA plasmid vaccine CLYNAV into the salmon genome. EFSA J. 2017;15(1):e04689.
139. Nichols WW, Ledwith BJ, Manam SV, Troilo PJ. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci. 1995;772:30-9.
140. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res. 2008;42(1-3):219-32.
141. Gottlieb P, Utz PJ, Robinson W, Steinman L. Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform. Clinic Immunol. 2013;149(3):297-306.
142. Edwards DK, Jasny E, Yoon H, Horscroft N, Schanen B, Geter T, et al. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J Transl Med. 2017;15(1):1-18.
143. Fuller DH, Berglund P. Amplifying RNA vaccine development. N Engl J Med. 2020;382(25):2469-71.
144. Zhang L, Bai J, Liu J, Wang X, Li Y, Jiang P. Toll-like receptor ligands enhance the protective effects of vaccination against porcine reproductive and respiratory syndrome virus in swine. Vet Microbiol. 2013;164(3-4):253-60.
145. Reautschnig P, Vogel P, Stafforst T. The notorious RNA in the spotlight-drug or target for the treatment of disease. RNA biology. 2017;14(5):651-68.
146. Douville RN, Nath A. Human endogenous retroviruses and the nervous system. Handb Clin Neurol. 2014;123(12):465-85.
147. Campbell JD. Development of the CpG adjuvant 1018: a case study. Methods Mol Biol. 2017;1494(26):15-27.
148. Blakney AK, McKay PF, Yus BI, Aldon Y, Shattock RJ. Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Gene Ther. 2019;26(9):363-72.
149. Sekaly R-P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med. 2008;205(1):7-12.
150. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-20.
151. Dicks MDJ, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, et al. A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLOS ONE. 2012;7(7):e40385.
152. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med. 2008;14(6):617-21.
153. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clinic Infect Dis. 2008;46(11):1769-81.
154. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-97.
155. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78.
156. Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem. 2013;8(3):360-76.
157. Karch CP, Burkhard P. Vaccine technologies: From whole organisms to rationally designed protein assemblies. Biochem Pharmacol. 2016;120(9):1-14.
158. Eyigün CP, Yilmaz S, Gül C, Sengül A, Hacibektasoglu A, Van Thiel DH. A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults. J Viral Hepat. 1998;5(4):265-9.
159. Feenstra F, Van Rijn PA. Current and next-generation bluetongue vaccines: Requirements, strategies, and prospects for different field situations. Crit Rev Microbiol. 2017;43(2):142-55.
160. Keech C, Albert G, Reed P, Neal S, Plested JS, Zhu M, et al. First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine. MedRxiv. 2020;8(5):20168435.
161. Lövgren K, Morein B. The requirement of lipids for the formation of immunostimulating complexes (iscoms). Biotechnol Appl Biochem. 1988;10(2):161-72.
162. Magnusson SE, Altenburg AF, Bengtsson KL, Bosman F, de Vries RD, Rimmelzwaan GF, et al. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66(2):224-33.
163. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787-96.
164. Grgacic EVL, Anderson DA. Virus-like particles: Passport to immune recognition. Methods. 2006;40(1):60-5.
165. Andrus JK, Sherris J, Fitzsimmons JW, Kane MA, Aguado MT. Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement. Vaccine. 2008;26(Suppl 10):K87-92.
166. Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines. 2012;11(3):349-66.
167. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med. 2020;384(7):643-9.
168. Stone Jr CA, Rukasin CR, Beachkofsky TM, Phillips EJ. Immune‐mediated adverse reactions to vaccines. Br J Clin Pharmacol. 2019;85(12):2694-706.
169. Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem. 2021;36(4):1-13.
170. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
171. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-97.
172. Sadoff J, Gars ML, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. MedRxiv. 2020;9(23):20199604.
173. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383(24):2320-32.
174. Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152. MedRxiv. 2020;12(11):20210419.
175. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html.
176. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications. N Engl J Med. 2021;384(19):1866-8.
177. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. MedRxiv. 2020;12(24):20248822.
178. Davies NG, Jarvis CI, CMMID COVID-19 Working Group, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593: 270–274.
179. Reuschl AK, Thorne L, Zuliani Alvarez L, Bouhaddou M, Obernier K, Soucheray M, et al. Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant. bioRxiv. 2021;24:427991.
180. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. bioRxiv. 2021;1(25):428137.
181. Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. MedRxiv. 2021;3(7):21252647.
182. Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Alshammary H, Amoako AA, et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe. 2021;2(7):e283-e284.
183. Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. BioRxiv. 2021;4(23):441101.
184. Gupta RK. Will SARS-CoV-2 variants of concern affect the promise of vaccines? Nat Rev Immunol. 2021;21(8):340–341.
185. Kemp S, Harvey W, Datir R, Collier D, Ferreira I, Carabelii A, et al. Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/V70. bioRxiv. 2020:2020.12.14.422555.
186. Collier DA, De Marco A, Ferreira IA, Meng B, Datir RP, Walls AC, et al. Sensitivity of SARS-CoV-2 B. 1.1. 7 to mRNA vaccine-elicited antibodies. Nature. 2021:1-10.
187. Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, et al. Increased Resistance of SARS-CoV-2 Variant P. 1 to Antibody Neutralization. Cell Host Microbe. 2021:2021.03.01.433466.
188. Hon C-C, Lam T-Y, Shi Z-L, Drummond AJ, Yip C-W, Zeng F, et al. Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus. J Virol. 2008;82(4):1819-26.
189. Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, Rapp M, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021;29(5):819-33.
190. Fratev F. The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: A Free energy of perturbation study. bioRxiv. 2020:2020.12.23.424283.
191. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell host & microbe. 2021;29(1):44-57.
192. Bian L, Gao F, Zhang J, He Q, Mao Q, Xu M, et al. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert review of vaccines. 2021:1-9.
193. Tchesnokova V, Kulakesara H, Larson L, Bowers V, Rechkina E, Kisiela D, et al. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. bioRxiv. 2021:2021.02.22.432189.
194. Mohammadi E, Shafiee F, Shahzamani K, Ranjbar MM, Alibakhshi A, Ahangarzadeh S, et al. Novel and emerging mutations of SARS-CoV-2: Biomedical implications. Biomed Pharmacother. 2021;139:111599.
195. Shinde V, Bhikha S, Hossain Z, Archary M, Bhorat Q, Fairlie L, et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant. med Rxiv. 2021:2021.02.25.21252477.
196. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant. N Engl J Med. 2021;384(20):1885-98.
197. Cohen J. South Africa suspends use of AstraZeneca's COVID-19 vaccine after it fails to clearly stop virus variant. Science. 2021:2-7.
198. Wadman M, Cohen J. Novavax vaccine delivers 89% efficacy against COVID-19 in UK—but is less potent in South Africa. Science. 2021;12(2774).
199. Hitchings M, Ranzani OT, Torres MS, de Oliveira SB, Almiron M, Said R, et al. Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P. 1 variant transmission in Brazil: A test-negative case-control study. medRxiv. 2021:2021.04.07.21255081.
200. Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52(5):737-41.
| Files | ||
| Issue | Vol 20 No 6 (2021) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/ijaai.v20i6.8016 | |
| Keywords | ||
| COVID-19 COVID-19 vaccines SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Abdi Ghavidel A, Rojhannezhad M, Kazemi B, Bandehpour M. Effectiveness of Coronavirus Vaccines against Syndrome Coronavirus 2 (SARS-CoV-2) and Its New Variants. Iran J Allergy Asthma Immunol. 2021;20(6):647-671.
